Corporate ActionJul 2, 2026, 05:32 PM
Picard Medical Q1 Revenue +85%; Proposes Reverse Split, Class B Stock
AI Summary
Picard Medical, Inc. reported strong Q1 2026 financial results, including 85% year-over-year revenue growth and a 28% improvement in gross margin. The company also provided updates on its next-generation "Emperor" artificial heart platform, aiming for FDA Breakthrough Device designation in 2026. For its upcoming Annual Meeting, Picard Medical proposes a reverse stock split to address NYSE listing non-compliance and the creation of a new Class B common stock with enhanced voting rights.
Key Highlights
- Q1 revenue grew 85% year-over-year; gross margin improved by 28%.
- U.S. revenue increased 116%, comprising the majority of product revenue.
- Proposed reverse stock split (1-for-15 to 1-for-50) to meet NYSE listing requirements.
- Company received NYSE non-compliance notice for stockholders' equity and losses.
- Proposed creation of new Class B common stock with 15M authorized shares, 20 votes/share.
- Developing "Emperor" next-gen artificial heart; targeting FDA Breakthrough Device designation in 2026.
- Interim CEO Richard Fang assumed role after previous CEO Patrick's departure.
- 2026 Annual Meeting of Stockholders scheduled for July 17, 2026.
Price Impact
More from PMI